|
|
|
|
Callisto Pharmaceuticals Announces Dr. Moshe Talpaz
to Join Scientific Advisory Board
NEW YORK--(BUSINESS WIRE)--Oct. 21, 2003--Callisto Pharmaceuticals,
Inc. (OTCBB: CLSP
- News) announced that Dr. Moshe Talpaz, Chairman
of the Department of Bioimmunotherapy of The University of Texas
M. D. Anderson Cancer Center has become a member of Callisto's
Scientific Advisory
Board.
Dr. Talpaz, well known for his role in the clinical
development of Gleevec, is an internationally-recognized authority on
leukemia
and blood cancers. Dr. Talpaz continues to be involved in the
clinical development of numerous cancer drugs, and has been a pioneer
in developing
currently
accepted treatment protocols especially in the leukemia area. "I am
pleased to be working with Callisto on the clinical development of Atiprimod
which represents a new non-classical therapeutic approach to the treatment
of multiple myeloma. This drug tackles key cellular signals that drive this
terrible disease" says Dr. Talpaz. "We at Callisto are delighted
to have someone of Dr. Talpaz's experience and stature on our Scientific
Advisory Board. Dr. Talpaz brings a world of knowledge in designing and
running clinical trials, something that will be pivotal to us as we move
forward with our lead drug candidate, Atiprimod, into the clinic." says
Dr. Gary S. Jacob, CEO of Callisto Pharmaceuticals, Inc.
About Callisto Pharmaceuticals, Inc.
Callisto is a biopharmaceutical company primarily focused on
the development of drugs to treat multiple myeloma, osteolytic
bone disease and other cancers. Callisto's lead drug candidate, Atiprimod,
is
a small-molecule,
orally available drug with antiproliferative and antiangiogenic
activity. Atiprimod successfully completed Phase I clinical trials
in rheumatoid arthritis
patients and Callisto filed an IND on September 23, 2003 with
the U.S. Food and Drug Administration on Atiprimod to enter
a Phase
I/IIa clinical
trial
in multiple myeloma patients. The drug is also being explored
as an agent to treat osteolytic bone disease. In addition,
Callisto has programs
focused
on the development of an analog of the human intestinal hormone,
uroguanylin, to treat colon cancer, and drugs to protect against
staphylococcal and streptococcal
bioweapons, as a protection against the devastating effects of
toxic shock syndrome. Callisto has two operating subsidiaries,
Callisto Research Labs,
LLC and Synergy Pharmaceuticals Inc.
Included in this release are "forward-looking: statements. Such statements
are indicated by words such as "expect," "should," "anticipate" and
similar words indicating uncertainty in facts and figures. Although
Callisto believes that the expectations reflected in such forward-looking
statements
are reasonable, it can give no assurance that such expectations
reflected in such forward-looking statements will prove to have been correct.
Callisto's
actual results could differ materially from those anticipated in
the forward-looking statements as a result of various factors.
|
|
|
|
|